XML 74 R63.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue recognition - Narrative (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 31, 2021
USD ($)
Sep. 30, 2021
USD ($)
Distributor
Sep. 30, 2020
USD ($)
Distributor
Sep. 30, 2021
USD ($)
segment
Distributor
Sep. 30, 2020
USD ($)
Distributor
Dec. 31, 2020
USD ($)
Nov. 30, 2011
USD ($)
Revenue recognition              
Number of operating segments | segment       1      
Number of distributors | Distributor   2 2 2 2    
Contract with customer, liability   $ 0   $ 0   $ 4,200,000  
Contract with customer, asset   0   0   $ 0  
Performance obligations satisfied in period     $ 2,000,000.0 4,000,000.0 $ 6,000,000.0    
Deferred consideration payable   0   0      
Remaining potential milestones that can be achieved   325,000,000.0   325,000,000.0      
Revenue   $ 138,743,000 $ 118,404,000 $ 373,364,000 $ 261,902,000    
Minimum              
Revenue recognition              
Percentage of net product sales threshold   10.00% 10.00% 10.00% 10.00%    
Net product revenue              
Revenue recognition              
Revenue   $ 115,605,000 $ 82,708,000 $ 309,998,000 $ 226,143,000    
Net product revenue | Non-US              
Revenue recognition              
Revenue   68,500,000 44,200,000 170,200,000 124,000,000.0    
Emflaza | United States              
Revenue recognition              
Revenue   47,100,000 38,500,000 139,800,000 102,100,000    
Translarna | Non-US              
Revenue recognition              
Revenue   67,200,000 43,400,000 166,300,000 122,700,000    
Collaboration revenue              
Revenue recognition              
Revenue   10,011,000 35,000,000 30,018,000 35,063,000    
Royalty revenue              
Revenue recognition              
Revenue   13,127,000 696,000 33,348,000 696,000    
SMA License Agreement | Collaboration revenue              
Revenue recognition              
Revenue   10,000,000.0 35,000,000.0 30,000,000.0 35,100,000    
SMA License Agreement | Royalty revenue              
Revenue recognition              
Revenue   13,100,000 700,000 33,300,000 700,000    
SMA License Agreement | Roche And SMA Foundation | Collaboration revenue              
Revenue recognition              
Revenue   10,000,000.0 $ 35,000,000.0 30,000,000.0 $ 35,100,000    
Research And Development Event Milestones | SMA License Agreement              
Revenue recognition              
Milestone payments received $ 10,000,000.0            
Research And Development Event Milestones | SMA License Agreement | Maximum              
Revenue recognition              
Remaining potential milestones that can be achieved             $ 135,000,000.0
Sales Milestones | SMA License Agreement              
Revenue recognition              
Remaining potential milestones that can be achieved   $ 325,000,000.0   $ 325,000,000.0      
Sales Milestones | SMA License Agreement | Maximum              
Revenue recognition              
Remaining potential milestones that can be achieved             $ 325,000,000.0